While circHIPK3 is frequently downregulated in cancer and positively correlated to good clinical outcomes (Li et al., 2017; Okholm et al., 2017), IGF2BP2 enhances genomic instability, is upregulated in cancer, and involved in cancer progression (Barghash et al., 2016; Kessler et al., 2015; Ye et al., 2016). Here, IGF2BP2 is linked to cancer.